CRISPR-Cas9 Gene Therapy Shows Promise in Treating Sickle Cell Disease and β-Thalassemia

Strategic Insights -

Researchers from Najran University have published a review highlighting the potential of CRISPR-Cas9 gene therapy in treating sickle cell disease (SCD) and β-thalassemia (BT). According to the study, SCD and BT affect millions of people worldwide, with approximately 500,000 infants born with SCD and 60,000 people diagnosed with BT every year.

Key Takeaways:

  • Sickle cell disease and β-thalassemia are caused by mutations in the hemoglobin subunit beta (HBB) gene, which leads to abnormal sickle hemoglobin and reduced hemoglobin production, respectively.
  • CRISPR-Cas9 gene therapy has shown promise in correcting both SCD and BT-causing mutations, as well as reactivating the expression of hemoglobin F (HbF) and regulating LRF and BCL11A.
  • Several clinical trials are ongoing to explore the potential of CRISPR-Cas9 gene-edited therapies in treating BT and SCD.
  • The study discusses the genetics and pathophysiological mechanisms of SCD and BT, as well as the mechanism of CRISPR-Cas9-mediated gene editing and common delivery methods of the CRISPR system.
  • Despite the potential of CRISPR-Cas9 gene therapy, the study highlights the current challenges and future perspectives on its application in treating SCD and BT.

Statistics:

  • Approximately 500,000 infants are born with sickle cell disease each year.
  • 60,000 people are diagnosed with β-thalassemia every year.
  • CRISPR-Cas9 gene therapy has shown effectiveness in correcting both SCD and BT-causing mutations.
  • The study highlights the need for further research to explore the applications and current status of CRISPR-Cas9-mediated gene editing in SCD and BT.

Sources:

  • NewsRx. Reports Summarize Gene Therapy Findings from Najran University [Therapeutic Promise of Crispr-cas9 Gene Editing In Sickle Cell Disease and (3-thalassemia: a Current Review]. Hematology Week. July 7, 2025; p 135.
  • Current Research In Translational Medicine. Therapeutic Promise of Crispr-cas9 Gene Editing In Sickle Cell Disease and (3-thalassemia: a Current Review. 2025;73(3).